Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209532 · ClinicalTrials.gov registry record · NA
A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
A NA study of Endometrial Cancer and Cervical Cancer, sponsored by Novadaq Technologies ULC, now a part of Stryker.
- Completed
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 8
- Study locations
NCT02209532 is a NA study of Endometrial Cancer and Cervical Cancer that has completed, run by Novadaq Technologies ULC, now a part of Stryker. The registered enrollment target is 180 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (66% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT02209532, a NA study of Endometrial Cancer and Cervical Cancer, has completed, sponsored by Novadaq Technologies ULC, now a part of Stryker.
- COMPLETED
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and cervical malignancies who are undergoing LN mapping.
Conditions Studied
Interventions
- DEVICE PINPOINT
Study Locations (8)
California
- O'Connor Hospital - San Jose
Florida
- Lee Memorial Hospital - Fort Myers
New York
- Memorial Sloan Kettering - New York
North Carolina
- Duke Cancer Institute - Durham
Texas
- MD Anderson Cancer Center - Houston
Ontario
- Sunnybrook Health Science Centre - Toronto
Quebec
- CHU de Québec - Université Laval - Québec
Other
- Hospital HIMA San Pablo - Caguas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209532
The ClinicalTrials.gov registry entry for NCT02209532 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (66% lower). The listed sponsor is Novadaq Technologies ULC, now a part of Stryker, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which PINPOINT is the first listed.
NCT02209532 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT02209532 about?
NCT02209532 is a clinical study titled "A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping". This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and cervical malignancies who are undergoing LN mapping.
What is the current status of trial NCT02209532?
This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2015-12. Estimated completion is 2017-06.
What conditions does trial NCT02209532 study?
This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer, Uterine Cancer.
What interventions are being tested in trial NCT02209532?
The interventions under investigation include: PINPOINT (DEVICE).
Who is sponsoring clinical trial NCT02209532?
This trial is sponsored by Novadaq Technologies ULC, now a part of Stryker, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02209532 being conducted?
This trial has 8 study locations across California, Florida, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
RECRUITING · NA
-
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
RECRUITING · NA
-
Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.